Biohaven Pharmaceutical: RBC’s $62 Target and Growth
RBC Capital Markets initiates coverage on Biohaven Pharmaceutical, assigning an outperform rating with a $62 price target. The firm praises ...
- Latest
- Trending
RBC Capital Markets initiates coverage on Biohaven Pharmaceutical, assigning an outperform rating with a $62 price target. The firm praises ...
Aurinia Pharmaceuticals downgraded by Bloom Burton & Co. as they halt drug development and implement workforce reduction. Implications for future ...
Digital Realty's strong Q4 2023 results and plans for 2024, including new ventures and capital recycling efforts, point to continued ...
Insilico Medicine and University of Toronto collaborate to target "undruggable" cancer genes using AI-designed molecules. AI is revolutionizing drug discovery ...
Essential Properties Realty Trust reports strong Q4 2023 results, showing significant investment activity and growth in AFFO per share. The ...
Curtiss-Wright achieves unprecedented financial performance in 2023, with strong growth expected in 2024. Investor Day event to discuss long-term strategy ...
Cenovus Energy has reported record production and strong financial performance in Q4 2023, with a significant reduction in net debt. ...
Wyndham Hotels & Resorts had a remarkable year in 2023, with impressive performance across various metrics. The company achieved record-breaking ...
Targa Resources achieved record-setting performance in Q4 2023, with a 22% increase in adjusted EBITDA. The company has outlined an ...
Four Corners Property Trust (FCPT) reports steady increase in AFFO per share and record year of acquisitions, showcasing resilience and ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.